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A turning point in leprosy therapy occurred in 1981 
when the World Health Organization (WHO) recom-
mended using multidrug therapy (MDT), with dapsone 
and rifampicin for six months for paucibacillary (PB) pa-
tients (MDT-PB) and 24 months of dapsone, rifampicin 
and clofazimine for multibacillary (MB) patients (MDT-
MB). In 1998, the WHO recommended a fixed duration 
of 12 months for treating MB patients (WHO 1998). The 
current WHO recommended treatment regimen for MB 
patients is 12 600 mg doses of rifampicin once a month, 
300 mg of clofazimine once a month plus 50 mg daily 
and 100 mg of dapsone daily. For PB patients, the regi-
men is six 600 mg doses of rifampicin once a month and 
100 mg of dapsone daily.
Despite the efficacy of the currently recommended 
leprosy MDT (Cellona et al. 2003, Morel 2004, Penna et 
al. 2011), there are some limitations, such as a prolonged 
treatment duration that leads to high drop-out rates, diffi-
culties in general health practitioners classifying the clini-
cal types and wrong diagnoses of the PB and MB types 
when based solely on the number of lesions (Huikeshoven 
1985, Ellard et al. 1988, Dasamanjali et al. 1997). Such dif-
ficulties have led several researchers to search for a uni-
form and shorter MDT (U-MDT) for the different leprosy 
types (Ji & Saunderson 2003, Talhari & Penna 2005) to 
replace the current regular MDT (R-MDT) that requires 
six and 12 months of treatment for PB and MB patients, 
respectively. Recently, the WHO raised the possibility 
that PB and MB patients might be treated for six months 
(WHO 2002) based on the following factors: MDT has 
been proven efficacious and safe, there are very few re-
ports of MDT resistance and relapse rates are low (< 1%) 
(Gelber et al. 2004, Matsuoka et al. 2007, WHO 2009).
Although U-MDT can represent an important advance 
in disease control, the recognised differences between the 
multi and PB groups should be considered, such as the 
bacillary charge (Ji 2001, Ji & Saunderson 2003), histo-
pathological findings (Sarno & Sampaio 1996) and im-
munological (Goulart et al. 2002) and genetic (Mira et al. 
2004, Moraes et al. 2004) profiles. Consequently, there is 
great concern regarding the possible impacts of U-MDT 
over several aspects of leprosy treatment, particularly 
therapy efficacy among MB patients and the incidence of 
adverse drug reactions in the patients with the PB type.
In 2007, an independent Brazilian study, the Brazilian 
U-MDT Clinical Trial (U-MDT/CT-Br), was initiated; in 
the study, dapsone, rifampicin and clofazimine were ad-
ministered over six months to all leprosy patients (LPs). 
Here, we present the results of an investigation that was 
performed in the context of the U-MDT/CT-Br project 
with respect to comparing the incidence of adverse ef-
fects in two situations: (i) PB and MB patients who were 
treated with the same regimen (U-MDT) and (ii) PB 
patients who were treated with either the PB (R-MDT) 
or the MB (U-MDT) regimen. We hope our results will 
be useful in supporting the decision making process for 
implementing U-MDT as an efficacious disease control 
strategy (Penna 2011).
SUBJECTS, MATERIALS AND METHODS
This study is part of an independent study (U-MDT/
CT-Br) coordinated by the Tropical Medicine Depart- 
ment of the University of Brasília (UnB) with the par-
ticipation of the Institute of Public Health and Tropical 
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This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This 
quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. 
Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed 
and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a stan-
dard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). 
Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with 
U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence 
of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or 
other side effects across groups of patients with TT, BL or LL treated with U-MDT.
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Pathology of the Federal University of Goiás; funding 
was provided by the DECIT/CNPq (403293/2005-7). This 
study was conceptualised, designed and developed by the 
Tropical Medicine Department of the UnB in partnership 
with the Royal Tropical Institute of Amsterdam.
This quantitative, prospective, nested study was de-
veloped at the Dona Libânia Center for Dermatology 
(CDERM) in Fortaleza, state of Ceará, Brazil. The data 
were collected from November 2007-November 2008. 
The targeted patients were those with diagnosed leprosy 
who were treated at the CDERM in the U-MDT/CT-Br 
study. The U-MDT/CT-Br is an open label randomised 
clinical trial design that was used to compare two treat-
ment regimens (R-MDT treatment vs. U-MDT treat-
ment) with monthly follow-ups for up to one year post-
treatment followed by yearly post-treatment visits for six 
years. Newly diagnosed, previously untreated PB and 
MB LPs, returning defaulters and relapse cases (provided 
that the last treatment dose was more than 5 years prior) 
ranging from six- 65 years of age were included in the 
study. Patients who were under tuberculosis treatment, 
steroid treatment, with overt signs of acquired immune 
deficiency syndrome or were unable to make monthly 
clinic visits during the treatment and follow-up periods 
were excluded. After being classified as either PB or MB 
based on the number of skin lesions, the patients were 
randomised and allocated into the trial. A random list of 
numbers for the study entrance sequence (according to 
the clinical report forms number) was prepared and the 
randomisation codes on the worksheet were covered with 
the same material that is used for lottery scratch cards; 
therefore, the printed numbers were not visible.
During the study period, 818 patients (all residents of 
the Fortaleza metropolitan area) were diagnosed with lep-
rosy and began treatment at the centre. Out these patients, 
430 were evaluated and 60 who presented with tubercu-
loid, borderline lepromatous (BL), or lepromatous leprosy 
(LL) types were selected based on unambiguous, rigor-
ous, clinical, bacteriological and histopathological criteria 
according to the Ridley and Jopling (1966) classification. 
These 60 patients were distributed into three groups. For-
ty PB patients were divided into two sub-groups: (i) 20 
patients were treated with MDT-PB treatment and (ii) 20 
with the MDT-MB for six months. The 20 MB remaining 
patients (14 LL and 6 BL leprosy) were treated with MDT-
MB for six months. None of the patients were removed 
from the study. The following exclusion criteria were ap-
plied: (i) patient wished to discontinue participation due to 
unavailability, procedure intolerance or any other person-
al reason, (ii) non-compliance with the experimental pro-
tocol, (iii) violation of the protocol, such as a histological 
finding that does not confirm leprosy, (iv) severe adverse 
events and/or signs or symptoms of possible severe toxic-
ity, (v) patient’s death during the study period, (vi) any 
other condition judged by the investigator to be necessary 
to maintain the health of the volunteer. 
The data were prospectively collected during the 
seven visits, as shown in Table I. The objective of the 
first visit was to select patients who had never received 
treatment. On the second visit (day 8 of the study), the 
TABLE I
Summary of visit activities
Visits 1 2 3 4 5 6 7
Inclusion criteria and/or patient discontinuation x x x x x x
Verification of diagnosis of leprosy onset x x
Information of risks and benefits of the study x
Signing of informed consent x
Filling out clinical report x x x x x x x
Investigation history of five year-prior treatment x
Clinical and dermatological evaluation x x x x x x
Evaluations of leprosy reactions x x x x x x x
Information on MDT adverse effects x x x x x
Clinical peripheral nerves evaluation x x x x x x
Neural pain scale x x x x x x x
Evaluation of peripheral nerve function x x x x x x x
Bacilloscopy x x
Biopsy for histopathological classification x
Clinical evaluation and disability classification x x
Classification of leprosy type x
Blood collection: complete haemogram, PCR and biochemistry x x x x x x
Recording of exam results x x x x x x
MDT supervised doses x x x
Evaluation of adverse effects x x x x x
Verification of simultaneous drug use x x x x x x x
MDT: multidrug therapy; PCR: polymerase chain reaction.
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clinical classification was performed and the patients re-
ceived the first supervised treatment dose. On the third 
visit (study day 9), recent adverse effects were evaluated 
and the study discontinuation criteria were addressed. 
On the fourth visit (day 15 of the study), late adverse 
effects were evaluated and the study discontinuation 
criteria were addressed. On the fifth visit (day 36), the 
adverse effects and possible study discontinuation were 
evaluated and the second supervised treatment dose was 
administered. The same procedures were performed on 
the sixth visit (day 148) and the final supervised dose of 
the treatment was administered. Finally, on the seventh 
visit (day 176 of the study), adverse effects were again 
evaluated and the patients were released.
The following adverse effects were monitored in 
the three groups: decreases in red blood cells (RBCs), 
haematocrit, haemoglobin, leucocytes and platelets, 
increases in the medium corpuscular volume, reticulo-
cytes, C reactive protein (CRP), bilirubin, leukocytes 
and serum activities of lactate dehydrogenase, serum 
glutamic oxaloacetic transaminase, serum glutamic 
pyruvic transaminase and alkaline phosphatase and the 
presence of jaundice, haepatomegaly, epigastric pain, 
nausea, anorexia, vomiting, abdominal pain, diarrhoea, 
dizziness, fatigue, headache, methemoglobinaemia, cy-
anosis, dyspnoea, psychosis, peripheral neuropathy, sul-
phone syndrome, agranulocytosis, acne, renal failure, 
flu-like syndrome, cutaneous pigmentation, xeroderma, 
constipation, acute abdominal pain, weight loss, lower 
limb oedema and drug-induced skin disorders (Cook 
1995, Matsuoka et al. 2007, Harminder et al. 2011).
Statistical analysis - The statistical analysis of the as-
sociation between the variables (adverse effects of drugs 
used in the MDT for leprosy) and the study groups (PB 
MDT-PB, PB MDT-MB and MB MDT-MB) was per-
formed using the non-parametric chi-squared test and 
the probability ratio. The adverse effects were grouped 
according to the most likely causative drug.
Ethic - The U-MDT/CT-Br study was performed un-
der the International (Helsinki) and Brazilian research 
regulations involving humans and was approved by 
three regional ethical committees from all of the states 
involved and by the National Ethics Commission. Writ-
ten informed consent was obtained from all the patients 
prior to inclusion in the study. For patients aged six-17 
years, written parental consent was obtained. Data con-
fidentiality was guaranteed and the patients were free to 
leave the study and opt for the R-MDT regimen at any 
time (ClinicalTrials.gov identifier - NCT00669643).
In addition, informed consent forms specifically 
prepared for this study were presented to the Ethical 
Committee on Research of the CDERM and approved 
by the National Ethics Commission of Research - Na-
tional Health Council/Ministry of Health, on February 
17 2006, protocol 001/06.
RESULTS
Tables II-IV describe the frequency of the adverse ef-
fects that were observed in each patient group according 
to the drug most likely to be the cause of the adverse ef-
fect. Haemolytic anaemia was the most frequent adverse 
TABLE II
Adverse effects observed, probably related to  
dapsone and/or rifampicin. Comparison between the  
paucibacillary (PB) groups on multidrug therapy  








↓ Red blood cellsa 13 (65) 19 (95)
↓ Haematocrita 13 (65) 19 (95)
↓ Haemoglobina 12 (60) 18 (90)
↑ MCVa 6 (30) 8 (40)
↑ Reticulocytesa 13 (65) 19 (95)
↑ LDHa 13 (65) 19 (95)
↑ SGOT 3 (15) 3 (15)
↑ SGPT 3 (15) 3 (15)
Epigastric pain 2 (10) 3 (15)
Nausea 3 (15) 2 (10)
Dizziness 2 (10) 0 (0)
Fatigue 3 (15) 2 (10)
Headache 4 (20) 3(15)
↑ Leukocytes 3 (15) 0 (0)
↓ Leukocytes 0 (0) 3 (15)
Abdominal pain 2 (10) 2 (10)
↑ Eosinophils 2(10) 4 (20)
a: statistically significant difference (p < 0.05) in the compari-
son between groups; LDH: lactate dehydrogenase; MCV: me-
dium corpuscular volume; SGOT: serum glutamic oxaloacetic 
transaminase; SGPT: serum glutamic pyruvic transaminase.
TABLE III
Adverse effects observed, probably related to dapsone and/or 
rifampicin comparison between paucibacillary (PB) and  








↓ Red blood cells 19 (95) 20 (100)
↓ Haematocrit 19 (95) 20 (100)
↓ Haemoglobin 18 (90) 18 (90)
↑ MCV 8 (40) 8 (40)
↑ Reticulocytes 19 (95) 20 (100)
↑ LDH 19 (95) 20 (100)
↑ SGOT 3 (15) 2(10)
↑ SGPT 3 (15) 2(10)
Epigastric pain 3 (15) 3 (15)
Nausea 2 (10) 2 (10)
Dizziness 0 (0) 2 (10)
Fatigue 2 (10) 2 (10)
Headache 3(15) 2 (10)
↑ Leukocytes 0 (0) 0 (0)
↓ Leukocytes 3 (15) 3 (15)
Abdominal pain 2 (10) 2 (10)
↑ Eosinophils 4 (20) 3 (15)
LDH: lactate dehydrogenase; MCV: medium corpuscular vol-
ume; SGOT: serum glutamic oxaloacetic transaminase; SGPT: 
serum glutamic pyruvic transaminase.
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effect, particularly in the groups treated with MDT-MB. 
Of the PB patients under MDT-MB, 30% presented with a 
haemoglobin index of < 10 g%, while none of the patients 
under MDT-PB presented with a haemoglobin index of < 
10 g%. Accordingly, we observed a statistically significant 
difference (p <0.05) between the PB groups on MDT-PB 
and MDT-MB in the distribution of the haematological 
alterations of the RBC index. No other statistically sig-
nificant difference was observed between the groups. 
To advance the understanding of the impact of MDT 
on the RBC index and the severity of haemolytic anae-
mia, the three groups were compared with respect to 
their distribution of haemoglobin values (obtained in the 
6th month of treatment), as shown in Tables IV, V. Again, 
statistically significant differences were observed only 
in the comparison between the PB groups undergoing 
the MDT-PB and MDT-MB treatments.
DISCUSSION
Of the adverse drug effects that were observed in the 
three study groups, haemolytic anaemia appeared with 
the greatest frequency, accompanied by the symptoms 
classically associated with it, such as headache, fatigue 
and dizziness. Such data suggest that administering folic 
acid would serve as a preventive and/or therapeutic mea-
sure for all patients undergoing MDT. 
The highest incidence of haemolytic anaemia was 
in the PB (95%) and MB groups (100%) treated with 
MDT-MB. A comparison to the PB patients who were 
treated with MDT-PB (65%, p < 0.05) suggests a role for 
clofazimine in developing these adverse effects (Chan-
Tompkins 1995).
Upon analysing the severity of anaemia at the end 
of the sixth month of treatment, no differences were ob-
served between the MB and PB patients under MDT-MB 
(25% vs. 30%, respectively) (Table VI), which indicates 
that the type of leprosy does not impact the severity of 
haemolytic anaemia. Instead, the statistically significant 
difference (p < 0.05) among the PB patients undergoing 
MDT-MB or MDT-PB suggests a possible influence of 
clofazimine on the severity of haemolytic anaemia (Ka-
toch et al. 1999).
Note that haemolytic anaemia, in addition to being in-
frequent, did not reach a degree of severity to indicate the 
suspension of dapsone and/or clofazimine for any of the 
patients. This observation, in conjunction with the pos-
sibility of controlling the condition with folic acid, argues 
in favour of the viability of MDT/MB for PB patients.
Finally, the adverse effects of dapsone, clofazimine 
and rifampicin were similar across the PB and the MB 
groups under MDT-MB, even after considering haemo-
lytic anaemia (95% vs. 100%). Furthermore, none of the 
other adverse effects were identified at a frequency or se-
verity that would indicate medical intervention. It is im-
portant to further highlight the absence of severe adverse 
effects attributed to dapsone (e.g., methemoglobinaemia, 
sulphone syndrome and agranulocytosis), rifampicin (re-
nal failure or flu-like syndrome), or clofazimine (semi-
occlusion, intestinal occlusion and acute abdominal pain) 
(Cook 1995). Despite this result, the total number of LPs 
worldwide using these drugs suggests strict surveillance 
of the adverse effects of MDT. In a literature search, we 
did not identify any studies that found synergistic effects 
of clofazimine and dapsone in the genesis of adverse ef-
fects in LPs. Additionally, there were no large controlled 
studies of the real prevalence of the adverse effects of 
R-MDT for comparison with our study.
Although PB and MB LPs presented bacteriological, 
immunological, histopathological, clinical and genetic 
differences, no differences in the incidence of adverse 
effects were observed in this study. Therefore, it is pos-
sible that the differences between PB and MB leprosy 
types have no influence on the pharmacokinetics of dap-
sone, rifampicin and clofazimine. 
TABLE V
Haemoglobin index (Hb) at the end  
of the sixth month of treatment. Comparison between  
paucibacillary (PB) groups on multidrug therapy (MDT)-PB 
and MDT-multibacillary (MB) treatment
Hb index 
(g%)
PB group on MDT-PB
n (%)
PB group on MDT-MB
n (%)
Hb < 10a 0 (0) 6 (30)
10 < Hb < 11 9 (45) 12 (60)
Hb > 1 a 11 (55) 2 (10)
a: statistically significant difference (p < 0.05) in the compari-
son between groups.
TABLE VI
Haemoglobin index (Hb) at the end of the sixth month  
of treatment. Comparison between the paucibacillary (PB)  
and multidrug therapy (MDT) groups, both using MDT-MB
Hb
(g%)
PB group on MDT-MB
n (%)
MB group on MDT-MB
n (%)
Hb < 10 6 (30) 5 (25)
10 < Hb < 11 12 (60) 11 (55)
Hb > 11 2 (10) 4 (20)
TABLE IV








Cutaneous pigmentation 2 (10) 1 (5)
Xeroderma 6 (30) 7 (35)
Abdominal pain 3 (15) 3 (15)
Nausea 2 (10) 2 (10)
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